Strata Critical Medical, Inc.
NASDAQ:SRTAAirlines, Airports & Air Services
-$0.03 today
- Market cap
- $443.03M
- Beta
- 2.20
- P/E (TTM)
- 9.7
- EPS (TTM)
- $0.60
Volume 0.99M
Average 0.91M
SRTA EBITDA Margin
EBITDA as a percentage of revenue.
Strata Critical Medical, Inc.NASDAQ: SRTA
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to 8.1%
EBITDA Margin was 8.1% in Q1 FY2026, up 11.4 pp from a year earlier. On a trailing-twelve-month basis it was -2.7%, up 5.5 pp year over year. Over 3 fiscal years it widened by 8.6 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 3 analysts of 0.8% for the fiscal year ending Dec 2026, up from -6.7% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- 8.1%+11.7 pp QoQ
- Last fiscal yearDec 2025
- -6.7%+2.0 pp YoY
- LTMMar 2026
- -2.7%+5.5 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +11.4 pp | +12.7 pp | +1.3 pp |
| 1 year | +2.0 pp | +7.4 pp | +5.4 pp |
| 3 years | +8.6 pp | +14.0 pp | +5.4 pp |
| 5 years | — | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -6.7%
- Year-over-year change
- +2.0pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -6.7% | +2.0pp |
| FY2024 | 2024-12-31 | -8.7% | +13.7pp |
| FY2023 | 2023-12-31 | -22.4% | -7.1pp |
| FY2022 | 2022-12-31 | -15.3% | +70.0pp |
| FY2021 | 2021-09-30 | -85.3% | — |
EBITDA Margin vs competitors
How SRTA compares with its peers on the latest reported figures
- SRTA's LTM Mar 2026 EBITDA Margin of -2.7% is the 8th highest of the 10 companies compared; the peer median is 4.3%.
- Its year-over-year change of +5.5 pp is the 5th highest of 10, against a peer median of +1.9 pp.
- Over three fiscal years its change of +8.6 pp compares with a peer median of +1.3 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Feb 2026 | 19.3% | +1.9 pp | +1.3 pp | |
| LTM Mar 2026 | 14.3% | +8.9 pp | -10.0 pp | |
| LTM Mar 2026 | 9.9% | +12.6 pp | +163.1 pp | |
| LTM Apr 2026 | 5.3% | -11.4 pp | -10.4 pp | |
| LTM Mar 2026 | 4.3% | +0.1 pp | +3.5 pp | |
| LTM Mar 2026 | 4.0% | -1.1 pp | -3.5 pp | |
| LTM Mar 2026 | -0.5% | +1.0 pp | +3.3 pp | |
SRTAStrata Critical Medical, Inc. | LTM Mar 2026 | -2.7% | +5.5 pp | +8.6 pp |
| LTM Mar 2026 | -3.5% | +31.1 pp | +110.6 pp | |
| LTM Mar 2026 | -3.9% | +8.8 pp | -14.4 pp | |
| FY2025 | — | — | — | |
| Peer median (excluding SRTA) | 4.3% | +1.9 pp | +1.3 pp | |
Competitors are the stored peer set for SRTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Sep 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 50.53M | 146.12M | 225.18M | 248.69M | 197.14M |
| Cost of Revenue | 40.01M | 123.85M | 183.06M | 189.77M | 158.82M |
| Gross Profit | 10.52M | 22.28M | 42.12M | 58.92M | 38.33M |
| Gross Margin | 20.8% | 15.2% | 18.7% | 23.7% | 19.4% |
| Research & Development | 1.68M | 5.55M | 4.63M | 3.18M | 3.05M |
| Selling, General & Admin | 32.93M | 70.26M | 105.61M | 89.66M | 45.08M |
| Operating Expenses | 34.61M | 75.8M | 110.24M | 92.85M | 48.13M |
| Depreciation & Amortization | 596K | 5.73M | 7.11M | 5.96M | 6.9M |
| EBITDA | (43.1M) | (22.31M) | (50.43M) | (21.6M) | (13.17M) |
| EBITDA Margin | -85.3% | -15.3% | -22.4% | -8.7% | -6.7% |
| Operating Income | (24.09M) | (53.53M) | (68.12M) | (33.93M) | (9.81M) |
| Operating Margin | -47.7% | -36.6% | -30.3% | -13.6% | -5.0% |
| Interest Income | 460K | 3.43M | 8.44M | 7.21M | 4.24M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (19.6M) | 25.5M | 10.58M | 6.36M | (10.26M) |
| Income Before Tax | (43.7M) | (28.03M) | (57.54M) | (27.56M) | (20.07M) |
| Pre-Tax Margin | -86.5% | -19.2% | -25.6% | -11.1% | -10.2% |
| Income Tax Expense | (3.64M) | (772K) | (1.47M) | (255K) | 0 |
| Net Income | (40.05M) | (27.26M) | (56.08M) | (27.31M) | (15.65M) |
| Net Margin | -79.3% | -18.7% | -24.9% | -11.0% | -7.9% |
| EPS (Basic) | (0.57) | (0.38) | (0.76) | (0.35) | (0.19) |
| EPS (Diluted) | (0.57) | (0.38) | (0.76) | (0.35) | (0.19) |
| Weighted Avg Shares | 70.1M | 71.24M | 73.52M | 77.5M | 82.45M |
| Weighted Avg Shares (Diluted) | 70.1M | 71.24M | 73.52M | 77.5M | 82.45M |
Strata Critical Medical, Inc.
NASDAQ:SRTA
Intrinsic Alpha fair value
Locked
Current Price
$4.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.